AD-Related N-Terminal Truncated Tau Is Sufficient to Recapitulate In Vivo the Early Perturbations of Human Neuropathology

Implications for Immunotherapy

A. Borreca, V. Latina, V. Corsetti, S. Middei, S. Piccinin, F. della Valle, R. Bussani, M. Ammassari-Teule, R. Nisticò, P. Calissano, G. Amadoro

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The NH2tau 26–44 aa (i.e., NH2htau) is the minimal biologically active moiety of longer 20–22-kDa NH2-truncated form of human tau—a neurotoxic fragment mapping between 26 and 230 amino acids of full-length protein (htau40)—which is detectable in presynaptic terminals and peripheral CSF from patients suffering from AD and other non-AD neurodegenerative diseases. Nevertheless, whether its exogenous administration in healthy nontransgenic mice is able to elicit a neuropathological phenotype resembling human tauopathies has not been yet investigated. We explored the in vivo effects evoked by subchronic intracerebroventricular (i.c.v.) infusion of NH2htau or its reverse counterpart into two lines of young (2-month-old) wild-type mice (C57BL/6 and B6SJL). Six days after its accumulation into hippocampal parenchyma, significant impairment in memory/learning performance was detected in NH2htau-treated group in association with reduced synaptic connectivity and neuroinflammatory response. Compromised short-term plasticity in paired-pulse facilitation paradigm (PPF) was detected in the CA3/CA1 synapses from NH2htau-impaired animals along with downregulation in calcineurin (CaN)-stimulated pCREB/c-Fos pathway(s). Importantly, these behavioral, synaptotoxic, and neuropathological effects were independent from the genetic background, occurred prior to frank neuronal loss, and were specific because no alterations were detected in the control group infused with its reverse counterpart. Finally, a 2.0-kDa peptide which biochemically and immunologically resembles the injected NH2htau was endogenously detected in vivo, being present in hippocampal synaptosomal preparations from AD subjects. Given that the identification of the neurotoxic tau species is mandatory to develop a more effective tau-based immunological approach, our evidence can have important translational implications for cure of human tauopathies.

Original languageEnglish
Pages (from-to)1-30
Number of pages30
JournalMolecular Neurobiology
DOIs
Publication statusAccepted/In press - Mar 5 2018

Fingerprint

Tauopathies
Immunotherapy
Intraventricular Infusions
Calcineurin
Presynaptic Terminals
Inbred C57BL Mouse
Neurodegenerative Diseases
Synapses
Down-Regulation
Learning
Phenotype
Amino Acids
Control Groups
Peptides
Neuropathology
Proteins
Genetic Background

Keywords

  • Alzheimer’s disease
  • Immunotherapy
  • Tau cleavage
  • Tau protein
  • Tauopathies

ASJC Scopus subject areas

  • Neuroscience (miscellaneous)
  • Neurology
  • Cellular and Molecular Neuroscience

Cite this

AD-Related N-Terminal Truncated Tau Is Sufficient to Recapitulate In Vivo the Early Perturbations of Human Neuropathology : Implications for Immunotherapy. / Borreca, A.; Latina, V.; Corsetti, V.; Middei, S.; Piccinin, S.; della Valle, F.; Bussani, R.; Ammassari-Teule, M.; Nisticò, R.; Calissano, P.; Amadoro, G.

In: Molecular Neurobiology, 05.03.2018, p. 1-30.

Research output: Contribution to journalArticle

Borreca, A, Latina, V, Corsetti, V, Middei, S, Piccinin, S, della Valle, F, Bussani, R, Ammassari-Teule, M, Nisticò, R, Calissano, P & Amadoro, G 2018, 'AD-Related N-Terminal Truncated Tau Is Sufficient to Recapitulate In Vivo the Early Perturbations of Human Neuropathology: Implications for Immunotherapy', Molecular Neurobiology, pp. 1-30. https://doi.org/10.1007/s12035-018-0974-3
Borreca, A. ; Latina, V. ; Corsetti, V. ; Middei, S. ; Piccinin, S. ; della Valle, F. ; Bussani, R. ; Ammassari-Teule, M. ; Nisticò, R. ; Calissano, P. ; Amadoro, G. / AD-Related N-Terminal Truncated Tau Is Sufficient to Recapitulate In Vivo the Early Perturbations of Human Neuropathology : Implications for Immunotherapy. In: Molecular Neurobiology. 2018 ; pp. 1-30.
@article{c965bbda82bf444bada08cf8215c0d19,
title = "AD-Related N-Terminal Truncated Tau Is Sufficient to Recapitulate In Vivo the Early Perturbations of Human Neuropathology: Implications for Immunotherapy",
abstract = "The NH2tau 26–44 aa (i.e., NH2htau) is the minimal biologically active moiety of longer 20–22-kDa NH2-truncated form of human tau—a neurotoxic fragment mapping between 26 and 230 amino acids of full-length protein (htau40)—which is detectable in presynaptic terminals and peripheral CSF from patients suffering from AD and other non-AD neurodegenerative diseases. Nevertheless, whether its exogenous administration in healthy nontransgenic mice is able to elicit a neuropathological phenotype resembling human tauopathies has not been yet investigated. We explored the in vivo effects evoked by subchronic intracerebroventricular (i.c.v.) infusion of NH2htau or its reverse counterpart into two lines of young (2-month-old) wild-type mice (C57BL/6 and B6SJL). Six days after its accumulation into hippocampal parenchyma, significant impairment in memory/learning performance was detected in NH2htau-treated group in association with reduced synaptic connectivity and neuroinflammatory response. Compromised short-term plasticity in paired-pulse facilitation paradigm (PPF) was detected in the CA3/CA1 synapses from NH2htau-impaired animals along with downregulation in calcineurin (CaN)-stimulated pCREB/c-Fos pathway(s). Importantly, these behavioral, synaptotoxic, and neuropathological effects were independent from the genetic background, occurred prior to frank neuronal loss, and were specific because no alterations were detected in the control group infused with its reverse counterpart. Finally, a 2.0-kDa peptide which biochemically and immunologically resembles the injected NH2htau was endogenously detected in vivo, being present in hippocampal synaptosomal preparations from AD subjects. Given that the identification of the neurotoxic tau species is mandatory to develop a more effective tau-based immunological approach, our evidence can have important translational implications for cure of human tauopathies.",
keywords = "Alzheimer’s disease, Immunotherapy, Tau cleavage, Tau protein, Tauopathies",
author = "A. Borreca and V. Latina and V. Corsetti and S. Middei and S. Piccinin and {della Valle}, F. and R. Bussani and M. Ammassari-Teule and R. Nistic{\`o} and P. Calissano and G. Amadoro",
year = "2018",
month = "3",
day = "5",
doi = "10.1007/s12035-018-0974-3",
language = "English",
pages = "1--30",
journal = "Molecular Neurobiology",
issn = "0893-7648",
publisher = "Humana Press Inc.",

}

TY - JOUR

T1 - AD-Related N-Terminal Truncated Tau Is Sufficient to Recapitulate In Vivo the Early Perturbations of Human Neuropathology

T2 - Implications for Immunotherapy

AU - Borreca, A.

AU - Latina, V.

AU - Corsetti, V.

AU - Middei, S.

AU - Piccinin, S.

AU - della Valle, F.

AU - Bussani, R.

AU - Ammassari-Teule, M.

AU - Nisticò, R.

AU - Calissano, P.

AU - Amadoro, G.

PY - 2018/3/5

Y1 - 2018/3/5

N2 - The NH2tau 26–44 aa (i.e., NH2htau) is the minimal biologically active moiety of longer 20–22-kDa NH2-truncated form of human tau—a neurotoxic fragment mapping between 26 and 230 amino acids of full-length protein (htau40)—which is detectable in presynaptic terminals and peripheral CSF from patients suffering from AD and other non-AD neurodegenerative diseases. Nevertheless, whether its exogenous administration in healthy nontransgenic mice is able to elicit a neuropathological phenotype resembling human tauopathies has not been yet investigated. We explored the in vivo effects evoked by subchronic intracerebroventricular (i.c.v.) infusion of NH2htau or its reverse counterpart into two lines of young (2-month-old) wild-type mice (C57BL/6 and B6SJL). Six days after its accumulation into hippocampal parenchyma, significant impairment in memory/learning performance was detected in NH2htau-treated group in association with reduced synaptic connectivity and neuroinflammatory response. Compromised short-term plasticity in paired-pulse facilitation paradigm (PPF) was detected in the CA3/CA1 synapses from NH2htau-impaired animals along with downregulation in calcineurin (CaN)-stimulated pCREB/c-Fos pathway(s). Importantly, these behavioral, synaptotoxic, and neuropathological effects were independent from the genetic background, occurred prior to frank neuronal loss, and were specific because no alterations were detected in the control group infused with its reverse counterpart. Finally, a 2.0-kDa peptide which biochemically and immunologically resembles the injected NH2htau was endogenously detected in vivo, being present in hippocampal synaptosomal preparations from AD subjects. Given that the identification of the neurotoxic tau species is mandatory to develop a more effective tau-based immunological approach, our evidence can have important translational implications for cure of human tauopathies.

AB - The NH2tau 26–44 aa (i.e., NH2htau) is the minimal biologically active moiety of longer 20–22-kDa NH2-truncated form of human tau—a neurotoxic fragment mapping between 26 and 230 amino acids of full-length protein (htau40)—which is detectable in presynaptic terminals and peripheral CSF from patients suffering from AD and other non-AD neurodegenerative diseases. Nevertheless, whether its exogenous administration in healthy nontransgenic mice is able to elicit a neuropathological phenotype resembling human tauopathies has not been yet investigated. We explored the in vivo effects evoked by subchronic intracerebroventricular (i.c.v.) infusion of NH2htau or its reverse counterpart into two lines of young (2-month-old) wild-type mice (C57BL/6 and B6SJL). Six days after its accumulation into hippocampal parenchyma, significant impairment in memory/learning performance was detected in NH2htau-treated group in association with reduced synaptic connectivity and neuroinflammatory response. Compromised short-term plasticity in paired-pulse facilitation paradigm (PPF) was detected in the CA3/CA1 synapses from NH2htau-impaired animals along with downregulation in calcineurin (CaN)-stimulated pCREB/c-Fos pathway(s). Importantly, these behavioral, synaptotoxic, and neuropathological effects were independent from the genetic background, occurred prior to frank neuronal loss, and were specific because no alterations were detected in the control group infused with its reverse counterpart. Finally, a 2.0-kDa peptide which biochemically and immunologically resembles the injected NH2htau was endogenously detected in vivo, being present in hippocampal synaptosomal preparations from AD subjects. Given that the identification of the neurotoxic tau species is mandatory to develop a more effective tau-based immunological approach, our evidence can have important translational implications for cure of human tauopathies.

KW - Alzheimer’s disease

KW - Immunotherapy

KW - Tau cleavage

KW - Tau protein

KW - Tauopathies

UR - http://www.scopus.com/inward/record.url?scp=85045155165&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045155165&partnerID=8YFLogxK

U2 - 10.1007/s12035-018-0974-3

DO - 10.1007/s12035-018-0974-3

M3 - Article

SP - 1

EP - 30

JO - Molecular Neurobiology

JF - Molecular Neurobiology

SN - 0893-7648

ER -